24/7 Market News Snapshot 05 September, 2024 – Hoth Therapeutics, Inc. Common Stock (NASDAQ:HOTH)

September 5, 2024

DENVER, Colo., 05 September, 2024 (247marketnews.com) – (NASDAQ:HOTH) are discussed in this article.
Hoth Therapeutics, Inc. (NASDAQ:HOTH) is experiencing a notable bullish trend, trading at $0.827 with a 16.5% rise from its previous close of $0.710, supported by a trading volume of 5.68 million shares. This significant volume indicates robust investor interest and suggests a potential breakout as the company’s stock appears to be poised for further upward movement.

In addition to the promising stock performance, Hoth Therapeutics is making waves in the clinical space with its innovative therapy, HT-001, specifically designed to treat epidermal growth factor receptor inhibitor (EGFRI)-associated papulopustular eruptions (PPEs). A recent case study has uncovered the remarkable effectiveness of HT-001 in alleviating severe skin toxicities related to cancer treatments. Notably, a 59-year-old metastatic breast cancer patient demonstrated significant symptom relief and complete lesion resolution just one week after starting treatment, allowing her to discontinue the therapy without any recurrence of lesions over the following three weeks.

Given that EGFRIs are critical in treating various cancers but often come with debilitating cutaneous side effects affecting up to 90% of patients, HT-001 offers a vital solution to ensure patients can continue their essential therapies without interruption. Robb Knie, CEO of Hoth Therapeutics, emphasized the company’s excitement over the initial findings, highlighting HT-001’s potential to significantly enhance quality of life for those affected by such side effects.

Hoth Therapeutics is advancing a Phase 2a clinical trial to further explore the safety and efficacy of HT-001 in managing EGFRI-related skin complications. The company’s commitment to developing impactful therapies is set to revolutionize treatment options and improve patient care for those navigating the challenges associated with cancer therapies.

Related news for (HOTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.